SEC Form 4 · accession 0001127602-17-031437
CONMED Corp · CNMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luke A Pomilio
Officer — EVP, Finance & CFO
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 12:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 3, 2017 | M | 10,020 | $39.87 | A | 44,472 | D | |
| Common StockF1 | Nov 3, 2017 | S | 10,020 | $53.57 | D | 34,452 | D | |
| Common Stock | Nov 3, 2017 | M | 8,000 | $16.46 | A | 42,452 | D | |
| Common Stock | Nov 3, 2017 | F | 5,277 | $53.37 | D | 37,175 | D | |
| Common Stock | Nov 3, 2017 | M | 10,000 | $19.26 | A | 47,175 | D | |
| Common Stock | Nov 3, 2017 | F | 6,854 | $53.37 | D | 40,321 | D | |
| Common Stock | Nov 3, 2017 | M | 10,000 | $27.63 | A | 50,321 | D | |
| Common Stock | Nov 3, 2017 | F | 7,626 | $53.37 | D | 42,695 | D | |
| Common Stock | Nov 3, 2017 | M | 10,000 | $26.09 | A | 52,695 | D | |
| Common Stock | Nov 3, 2017 | F | 7,484 | $53.37 | D | 45,211 | D | |
| Common Stock | Nov 3, 2017 | M | 9,600 | $32.93 | A | 54,811 | D | |
| Common Stock | Nov 3, 2017 | F | 7,790 | $53.37 | D | 47,021 | D | |
| Common Stock | Nov 3, 2017 | M | 4,680 | $44.90 | A | 51,701 | D | |
| Common Stock | Nov 3, 2017 | F | 4,315 | $53.37 | D | 47,386 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options To Purchase Common StockF2 | $39.87 | Nov 3, 2017 | M | 10,020 | D | — | Mar 1, 2026 | Common Stock | 10,020 | 40,080 | D |
| Sars (Stock Appreciation Rights)F3 | $16.46 | Nov 3, 2017 | M | 8,000 | D | — | Jun 1, 2019 | Common Stock | 8,000 | 0 | D |
| Sars (Stock Appreciation Rights)F3 | $19.26 | Nov 3, 2017 | M | 10,000 | D | — | Jun 1, 2020 | Common Stock | 10,000 | 0 | D |
| Sars (Stock Appreciation Rights)F3 | $27.63 | Nov 3, 2017 | M | 10,000 | D | — | Jun 1, 2021 | Common Stock | 10,000 | 0 | D |
| Sars (Stock Appreciation Rights)F3 | $26.09 | Nov 3, 2017 | M | 10,000 | D | — | Jun 1, 2022 | Common Stock | 10,000 | 0 | D |
| Sars (Stock Appreciation Rights)F3 | $32.93 | Nov 3, 2017 | M | 9,600 | D | — | Jun 1, 2023 | Common Stock | 9,600 | 2,400 | D |
| Sars (Stock Appreciation Rights)F3 | $44.90 | Nov 3, 2017 | M | 4,680 | D | — | Jun 1, 2024 | Common Stock | 4,680 | 3,120 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.55 to $53.595. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder."
- F2The incentive stock options ("ISOs") were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period
- F3The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.